Mechanisms of Toxicity from Excess EWS/FLI1 in Ewing Sarcoma
Official title: Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Funded at Dana-Farber Cancer Inst · NIH-11322022 · Data updated 2026-11-12
A pediatric bone cancer study looking at what happens when too much EWS/FLI1 protein is present in Ewing sarcoma cells and how this could reveal new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 7, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $713,593 |
| NIH project number | 5R01CA283395-04 |
| Project ID | NIH-11322022 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with Ewing sarcoma or related bone cancers who could participate in future translational studies or trials.
✕Less likely to help
The study itself does not directly enroll patients and may not benefit all bone cancer patients.
What this research studies
This grant explores how exceeding normal levels of the EWS/FLI1 fusion protein affects Ewing sarcoma cells and why too much can kill tumor cells. Researchers will use genetic tools like CRISPR and shRNA, along with protein degradation methods, to manipulate EWS/FLI1 levels and study the resulting cellular changes. They aim to uncover the molecular mechanisms that set a “Goldilocks” range for EWS/FLI1 and identify why high levels are harmful to cancer cells. The findings could illuminate broader principles of Ewing sarcoma biology and its relationship to other EWS fusion proteins, potentially guiding new therapeutic strategies.
Why it matters
Potential benefit: Understanding the harmful effects of excess EWS/FLI1 could lead to novel approaches that exploit this vulnerability in Ewing sarcoma.
How similar studies have gone: Preclinical work with EWS/FLI1 and viral/CRISPR approaches has shown that modulating fusion protein levels can impact cancer cell survival.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Stegmaier, Kimberly — Dana-Farber Cancer Inst
- Study coordinator: Stegmaier, Kimberly
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.